Radioiodine Therapy of Benign Thyroid Diseases: Graves’ Disease, Plummer’s Disease, Non-toxic Goiter and Nodules

Aktolun, Cumali; Urhan, Muammer

doi:10.1007/978-1-4614-4021-5_17

Cited by 2 publications

(4 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with moderate to severe active thyroid eye disease should be consider for thyroid surgery or ATD. However, therapeutic efficacy of RAI in such cases needs to be evaluated [22,23,43].…”

Section: Grave's Diseasementioning

confidence: 99%

“…Majority of the patients (~95%) achieves hypothyroidism in 2-3 months after therapy and decrease in serum TSH level can be seen in within a week after therapy. RAI therapy should be avoided in patients with active orbitopathy [22,43,44].…”

Section: Pediatric Grave's Diseasementioning

confidence: 99%

“…RAI is either given as fixed dose activity (10-20 mCi) or calculated on the basis of thyroid size and radioiodine uptake values using 150-200 μCi/gm calculated fixed dose. There is estimated 20% risk of treatment failure of TMNG and 6-18% for adenoma [22,43,45].…”

Section: Toxic Nodular Goitermentioning

confidence: 99%

See 2 more Smart Citations

Radioactive Iodine Therapy for Hyperthyroidism

Hussain¹,

Adil²,

Hussain³

2023

Hyperthyroidism - Recent Updates

View full text Add to dashboard Cite

Hyperthyroidism is one of the most commonly encountered endocrine disorder with potentially devastating health consequences. Radioactive iodine has been used for the treatment of hyperthyroidism since 1940s. It is now widely accepted as safe, cost-effective and reliable treatment option with 50–90% cure rate in first year after therapy. With long-term follow-up hypothyroidism is inevitable especially in Grave’s disease which can activate orbitopathy in predisposed individuals. Early and timely management of hypothyroidism is associated with better therapeutic outcomes. There is very little evidence of cardiovascular and cancer related mortality risk after radioactive iodine therapy. However, it is said that these risks appear to be thyroid hormone driven above all other factors.

show abstract

Section: Grave's Diseasementioning

confidence: 99%

Section: Pediatric Grave's Diseasementioning

confidence: 99%

See 1 more Smart Citation

Radioactive Iodine Therapy for Hyperthyroidism

Hussain¹,

Adil²,

Hussain³

2023

Hyperthyroidism - Recent Updates

View full text Add to dashboard Cite

show abstract

“…At present, the commonly used clinical treatment methods include radioactive iodine ( 131 I) treatment, antithyroid drug (ATD), and thyroidectomy [1] . Radioactive iodine 131 I therapy was introduced in the 1940s [2,3] . After 131 I enters the human body, it targets the thyroid gland, and has less distribution in other tissues and organs with short residence time, therefore, the radiation dose of conventional dose 131 I to gonad, bone marrow and liver is low, and generally will not cause serious radiation damage.…”

Section: Introductionmentioning

confidence: 99%

Prediction of 131i Therapeutic Dose and Prognosis in Hyperthyroidism Patients Using Mechanical Learning Model

Gao¹,

Yuan²,

Gao³

et al. 2021

Preprint

View full text Add to dashboard Cite

ObjectiveMultiple mechanical learning models were used to predict the therapeutic dose of 131I radionuclide in patients with hyperthyroidism, and to compare the calculation results of each prediction model to obtain the optimal model for dose prediction. Meanwhile, the classification model was used to classify the prognosis of the existing clinical hyperthyroidism case data in order to evaluate the administration results and provide reference for the dose given by clinicians.MethodsAccording to the data of hyperthyroidism patients treated with 131I in nuclear medicine department of many hospitals, a prediction model was established based on MATLAB. Firstly, the prediction results of BP neural network, radial basis function (RBF) neural network and support vector machine (SVM) were compared with small sample data, and then the optimal model was selected to predict the drug dose. BP-AdaBoost, SVM and random forest were used to classify the patients after recovery and evaluate whether the dose was accurate.ResultsThe average errors of BP neural network, RBF neural network and SVM models trained with small samples were 6.58%, 17.25% and 14.09% respectively. After comparison, BP neural network was selected to establish the prediction model. The data of 30 cases were randomly selected to verify BP neural network, and average error of the prediction results was 11.99%. Using SVM, BP-AdaBoost and random forest models, 100 groups of case data were selected as the training set and 10 groups as the test set. The classification accuracy were 80%, 90% and 100% respectively. The random forest model with the highest accuracy was selected as the large sample prediction. When 318 groups of cases were trained and 35 groups of cases were used for the test, the classification accuracy was 97.14%.ConclusionThis study compared the prediction effects of various prediction models on 131I therapeutic dose in patients with hyperthyroidism and the accuracy of prognosis classification. BP neural network and random forest achieved the best results respectively. The two models provide reference for clinicians when giving the dose, which has clinical practical significance.

show abstract

Radioiodine Therapy of Benign Thyroid Diseases: Graves’ Disease, Plummer’s Disease, Non-toxic Goiter and Nodules

Cited by 2 publications

References 70 publications

Radioactive Iodine Therapy for Hyperthyroidism

Radioactive Iodine Therapy for Hyperthyroidism

Prediction of 131i Therapeutic Dose and Prognosis in Hyperthyroidism Patients Using Mechanical Learning Model

Contact Info

Product

Resources

About